InsidersTradesSigma
MP
Medesis Pharma S.A. Stock: price and management transactions · France · AMF
Follow the Medesis Pharma S.A. stock price and the full insider trade history of the company, a listed equity based in France. Shares are listed on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, Medesis Pharma S.A. has logged 13 reports. The latest transaction was filed on 3 December 2024 (Cession). Among the most active insiders: Jean-Claude Maurel. The full history is free.
13
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€159,220
11 ops.
Sell Volume
30Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 3 December 2024
Declarations13 total
10,000 shares@ €0.41420.4% of flowActionEuronext Growth Paris2024DD1009191
2,388 shares@ €1.18480.3% of flowActionEuronext Growth Paris2024DD982311
4,000 shares@ €0.8160.3% of flowActionEuronext Growth Paris2024DD948054
4,000 shares@ €1.400.5% of flowActionEuronext Growth Paris2023DD922065
5,000 shares@ €1.420.6% of flowActionEuronext Growth Paris2023DD918618
3,140 shares@ €2.200.6% of flowActionEuronext Growth Paris2023DD913377
1,000 shares@ €3.000.3% of flowActionEuronext Growth Paris2022DD874723
5,000 shares@ €3.301.5% of flowActionEuronext Growth Paris2022DD859665
3,000 shares@ €3.15130.9% of flowActionEuronext Growth Paris2022DD857451
3,000 shares@ €3.47430.9% of flowActionEuronext Growth Paris2022DD848276
10,300 shares@ €5.24100.0% of flowActionHors plateforme de négociation2021DD812272
15,000 shares@ €6.00100.0% of flowActionEuronext Growth Paris2021DD768836
101,997 shares@ €10.2093.8% of flowActionHors plateforme de négociation2021DD760941
13 of 13 declarations
About Medesis Pharma S.A.
MEDESIS PHARMA S.A. is a French biopharmaceutical company listed on Euronext Growth Paris under ticker ALMDP (ISIN: FR0010844464). Founded in April 2003 by Jean-Claude Maurel, the company was established to consolidate and further develop intellectual property arising from earlier research on lipid components and their therapeutic potential. Headquartered near Montpellier, Medesis Pharma is positioned as a clinical-stage biotech focused on the design of drug candidates and innovative oral delivery systems for active pharmaceutical ingredients. The company’s business model is anchored in its proprietary AONYS® platform, a microemulsion/nanomicelle technology designed to deliver water-soluble molecules through the buccal route. The purpose of this platform is to improve bioavailability, simplify administration, and broaden the therapeutic scope of existing molecules. AONYS® underpins most of Medesis Pharma’s research and development pipeline. The company is therefore active across several therapeutic domains: neurodegenerative diseases, infectious and inflammatory diseases, certain cancers, radioprotection, and decorporation therapies for radionuclide exposure. Its flagship program is NanoLithium®, aimed at treating Alzheimer’s disease and also studied in Huntington’s disease. Recent corporate communications indicate meaningful clinical progress, including the completion of a clinical study in 2024 and encouraging results from the first phase of a trial. Medesis Pharma is also developing NanoManganese® for radioprotection and to enhance the efficacy and safety of radiotherapy in oncology, alongside programs intended for populations contaminated or irradiated after a nuclear accident. Historically, the company has also pursued COVID-19-related candidates and collaborative oncology programs. From a scientific and industrial standpoint, Medesis Pharma stands out for its highly targeted approach to diseases with substantial unmet medical need. The company emphasizes its patent portfolio, scientific publications, and a development strategy built around preclinical validation followed by clinical proof of concept. Its geographic footprint is mainly French, with a strong base near Montpellier, but its scientific and regulatory communications are international in scope, including presentations at specialized conferences and multi-site clinical development. As a niche biotech with high scientific ambition, Medesis Pharma remains exposed to the execution risks typical of drug development, yet it occupies a distinctive position in oral nanodelivery and next-generation pharmaceutical innovation.
